ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

July 3, 2023

Study Completion Date

July 3, 2023

Conditions

Obesity

Interventions

DRUG

ERX1000

ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension

DRUG

Placebo

A suspension containing magnesium hydroxide carbonate in polysorbate

Trial Locations (1)

Labcorp Clinical Research Unit Inc., Madison